by Kyle | Oct 4, 2022 | Press Release
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has received an initial order of 19,000...
by Kyle | Sep 29, 2022 | Press Release
Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,”...
by Kyle | Sep 19, 2022 | Press Release
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has signed an exclusive global commercial...
by Kyle | Jul 25, 2022 | News
The Rapid Quantitative Tear Test for MMP-9 from AXIM Biotechnologies Inc. was featured in a list of DED Diagnostic tools in Optometric Management.com. See the list below: DED Diagnostic Items* BLINK ASSESSMENT iPEDA Blink Analyzer MEIBOMIAN GLAND EXPRESSION Flexx MG...
by Kyle | Jul 21, 2022 | Press Release
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that its CEO John Huemoeller has been...
